ArticleMedicine2025
ANCA-associated vasculitis with crescentic glomerulonephritis and papillary thyroid carcinoma: A case report.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
rationaleANCA-associated vasculitis (AAV) is an autoimmune disease. Renal involvement in AAV can manifest as crescentic glomerulonephritis (CGN), which can lead to rapidly progressive renal failure. AAV with crescentic glomerulonephritis complicated and papillary thyroid carcinoma remains rare. The purpose of this report was to enhance the understanding of the diagnosis and treatment of AAV combined with crescentic glomerulonephritis and papillary thyroid carcinoma, reduce misdiagnosis and missed diagnosis, and for the patient with AAV, attention should be paid to screening for cancer, and multi-disciplinary collaboration is required for diagnosis and treatment. PATIENT CONCERNS: A 49-year-old female patient was admitted to our hospital because of weakness and poor appetite for the past 2 weeks and lower limb edema for the past 3 days. Pathological examination of the renal biopsy specimen showed large cellular crescents and the pathology of the thyroid tissue revealed papillary thyroid carcinoma. DIAGNOSES: This patient was diagnosed with AAV with crescentic glomerulonephritis complicated and papillary thyroid carcinoma.
interventionsTreatment with 500 mg/day methylprednisolone for 3 days (A total of 2 times, with an interval of 2 weeks between each time)and then 40 mg/day intravenously, cyclophosphamide 1 g pulse therapy and plasma exchange, hemodialysis and resection of the left lobe of the thyroid gland. Interventions, such as anti-infection, correct anemia and electrolyte imbalance, were administered. OUTCOMES: After treatment, Urine output had returned to normal, the blood creatinine level had remained below 200 µmol/L, and the patient was no longer dependent on hemodialysis. Her PR3 and c-ANCA turned negative. The thyroid cancer did not recur after follow-up of 1 year. LESSONS: AAV combined with papillary thyroid carcinoma is very rare, especially AAV with crescentic glomerulonephritis and papillary thyroid carcinoma. The pathogenesis between the 2 is still not clear. In addition to considering immunosuppressive agents, it is still necessary to consider the common pathogenic pathways of AAV itself or between AAV and cancers. When diagnosing AAV, attention should be paid to screening for cancer, and multi-disciplinary collaboration is required for diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.